The additional closing of RDiscovery Fund

News >The additional closing of RDiscovery Fund

The additional closing of RDiscovery Fund

05/28/2026

Remiges Ventures, a drug discovery venture capital firm with offices in Japan and the United States, is pleased to announce the additional closing of RDiscovery Fund, LP, a new venture fund focused on drug discovery incubation. The fund that reached $100 million is managed by RDiscovery, KK, Remiges Ventures' incubation subsidiary in Tokyo, Japan.

The RDiscovery Fund aims to promote VC-led translational science and new company formation for advanced drug discovery technologies from academia, research institutions, and pharmaceutical companies. By leveraging Remiges Ventures' global investment platform, unique incubation capabilities, and extensive network, the fund will invest in early-stage opportunities both in Japan and internationally.

The following companies have committed as limited partners (LPs):

• Japan Investment Corporation (Japan)
• ClavystBio (Singapore)
• Shin Nippon Biomedical Laboratories, Ltd. (Japan)
• FUJIFILM Corporation (Japan)
• Senju Pharmaceutical Co., Ltd. (Japan)
• Toray Industries, Inc. (Japan)
• GW2050 PROJECTS Promotion Council companies (Japan)
  ・The Okinawa Electric Power Company, Inc.
  ・Bank of The Ryukyus, Ltd.
  ・The Bank of Okinawa, Ltd.
  ・THE OKINAWA KAIHO BANK, LTD.
  ・Ryuseki Corporation
  ・Kokuba-Gumi Co., Ltd.
  ・Okinawa Cellular Telephone Company

RDiscovery Fund: Key Features and Vision

1. Pre-startup Support: RDiscovery takes the lead in investing in scientific discoveries prior to startup formation,bridging the gap to drug development.

2. Innovation Through IP Creation: The fund actively invests at the seed stage to create new intellectual property, transforming drug discovery innovations into fundable projects.

3. In-house Venture Creation: Based on translational results, RDiscovery establishes and supports drug discovery ventures, developing Japanese innovations into global companies.

4. Ecosystem Connection: The fund provides hands-on support for innovative drug discovery originating in Japan and connects these innovations to the global value chain.

5. Global Investment Strategy: Continuing Remiges Ventures' approach, the fund will invest in and provide hands-on support to leading drug discovery ventures across North America, Europe, Japan, and other regions.